The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

编者按：2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO-GU）盛大召开，前列腺癌领域迎来术语体系革新、多项重磅研究数据更新与治疗格局的迭代升级。会议期间，肿瘤瞭望-泌尿时讯特邀美国威尔康奈尔医学院Scott T.

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Read more about how low testosterone levels are linked to ‘extreme’ disease progression in patients with prostate cancer ...

Low testosterone may raise the risk of aggressive prostate cancer progression in men under monitoring, a study finds.

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...